Wawer, M. J. et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J. Infect. Dis. 191, 1403-1409

Department of Population and Family Health, Columbia University, New York, New York, United States
The Journal of Infectious Diseases (Impact Factor: 6). 06/2005; 191(9):1403-9. DOI: 10.1086/429411
Source: PubMed


We estimated rates of human immunodeficiency virus (HIV)-1 transmission per coital act in HIV-discordant couples by stage of infection in the index partner.
We retrospectively identified 235 monogamous, HIV-discordant couples in a Ugandan population-based cohort. HIV transmission within pairs was confirmed by sequence analysis. Rates of transmission per coital act were estimated by the index partner's stage of infection (recent seroconversion or prevalent or late-stage infection). The adjusted rate ratio of transmission per coital act was estimated by multivariate Poisson regression.
The average rate of HIV transmission was 0.0082/coital act (95% confidence interval [CI], 0.0039-0.0150) within approximately 2.5 months after seroconversion of the index partner; 0.0015/coital act within 6-15 months after seroconversion of the index partner (95% CI, 0.0002-0.0055); 0.0007/coital act (95% CI, 0.0005-0.0010) among HIV-prevalent index partners; and 0.0028/coital act (95% CI, 0.0015-0.0041) 6-25 months before the death of the index partner. In adjusted models, early- and late-stage infection, higher HIV load, genital ulcer disease, and younger age of the index partner were significantly associated with higher rates of transmission.
The rate of HIV transmission per coital act was highest during early-stage infection. This has implications for HIV prevention and for projecting the effects of antiretroviral treatment on HIV transmission.

Download full-text


Available from: Godfrey Kigozi,
  • Source
    • "During sexual transmission, HIV-1 viral particles or virus-infected cells have to overcome a series of obstacles to establish a successful infection including: mucus; the integrity of the genital or rectal epithelial barriers; host innate defense mechanisms; and the sparsity, activation state and susceptibility of mucosal CD4 + target cells (Borrow P, et al., 2010; Derdeyn C A, et al., 2004; Keele B F, et al., 2008; Miller C J, et al., 2005; Temchura V, et al., 2014; Tsai L, et al., 2014; Zhang Z Q, et al., 2004). These obstacles collectively result in a relatively low transmission rate per exposure (Boily M C, et al., 2009; Wawer M J, et al., 2005). However, potential selective advantages acquired by HIV-1, such as enhanced binding to specific cell subtypes, might significantly increase the chances of a successful transmission event. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HIV-1 envelope glycoprotein is reported to interact with α4β7, an integrin mediating the homing of lymphocytes to gut-associated lymphoid tissue, but the significance of α4β7 in HIV-1 infection remains controversial. Here, using HIV-1 strain BaL, the gp120 of which was previously shown to be capable of interacting with α4β7, we demonstrated that α4β7 can mediate the binding of whole HIV-1 virions to α4β7-expressing transfectants. We further constructed a cell line stably expressing α4β7 and confirmed the α4β7-mediated HIV-1 binding. In primary lymphocytes with activated α4β7 expression, we also observed significant virus binding which can be inhibited by an anti-α4β7 antibody. Moreover, we investigated the impact of antagonizing α4β7 on HIV-1 infection of primary CD4(+) T cells. In α4β7-activated CD4(+) T cells, both anti-α4β7 antibodies and introduction of short-hairpin RNAs specifically targeting α4β7 resulted in a decreased HIV-1 infection. Our findings indicate that α4β7 may serve as an attachment factor at least for some HIV-1 strains. The established approach provides a promising means for the investigation of other viral strains to understand the potential roles of α4β7 in HIV-1 infection.
    Virologica Sinica 12/2014; 29(6):381-92. DOI:10.1007/s12250-014-3525-8
  • Source
    • "Thus, it was highly unlikely that the trial included HIV-positive individuals during the acute stage of infection. The probability of HIV transmission for each unprotected coital act without treatment , p un-treat , was calculated from a normal distribution with the mean μ p ¼0.0015 and SE p ¼0.0001 [24] [25]. For each unprotected coital act, the simulation draws a random number from a uniform distribution, ranging from 0 to 1, to determine whether a HIV seronegative individual in the control group remains uninfected or becomes HIV-positive. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In this study, we illustrate the utility of agent-based simulation to inform trial design and how this supports outcome interpretation of randomized controlled trials (RCTs). We developed agent-based Monte Carlo models to simulate existing landmark HIV RCTs, such as the Partners in Prevention HSV/HIV Transmission Study. We simulated a variation of this study using valacyclovir therapy as the intervention, and we used a male circumcision RCT based on the Rakai Male Circumcision Trial. Our results indicate that a small fraction (20%) of the simulated Partners in Prevention HSV/HIV Transmission Study realizations rejected the null hypothesis, which was no effect from the intervention. Our results also suggest that an RCT designed to evaluate the effectiveness of a more potent drug regimen for HSV-2 suppression (valacyclovir therapy) is more likely to identify the efficacy of the intervention. For the male circumcision RCT simulation, the greater biological effect of the male circumcision yielded a major fraction (81%) of RCT realizations' that reject the null hypothesis, which was no effect from the intervention. Our study highlights how agent-based simulations synthesize individual variation in the epidemiological context of the RCT. This methodology will be particularly useful for designing RCTs aimed at evaluating combination prevention interventions in community-based RCTs, wherein an intervention's effectiveness is challenging to predict.
    Computers in Biology and Medicine 07/2014; 50. DOI:10.1016/j.compbiomed.2014.03.008 · 1.24 Impact Factor
  • Source
    • "Incident HIV infections necessarily result from transmission of the virus between an HIV-infected index case and an HIV-uninfected individual. HIV viral load is the key determinant of viral transmission, as demonstrated clearly in observational studies of sexual transmission among HIV-discordant couples; in those studies, no transmission was seen when the index case had a plasma viral load below 1,000 copies HIV ribonucleic acid (RNA)/mL [25,26]. By reducing plasma viral load to undetectable levels (<50 copies HIV RNA/mL), it is assumed that ART will also suppress viral burden in the genital tract to levels at which transmission is unlikely to occur [27,28], although genital shedding of HIV can sometimes occur even when plasma viraemia is suppressed [29]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Effective interventions to reduce HIV incidence in sub-Saharan Africa are urgently needed. Mathematical modelling and the HIV Prevention Trials Network (HPTN) 052 trial results suggest that universal HIV testing combined with immediate antiretroviral treatment (ART) should substantially reduce incidence and may eliminate HIV as a public health problem. We describe the rationale and design of a trial to evaluate this hypothesis. A rigorously-designed trial of universal testing and treatment (UTT) interventions is needed because: i) it is unknown whether these interventions can be delivered to scale with adequate uptake; ii) there are many uncertainties in the models such that the population-level impact of these interventions is unknown; and ii) there are potential adverse effects including sexual risk disinhibition, HIV-related stigma, over-burdening of health systems, poor adherence, toxicity, and drug resistance.In the HPTN 071 (PopART) trial, 21 communities in Zambia and South Africa (total population 1.2 m) will be randomly allocated to three arms. Arm A will receive the full PopART combination HIV prevention package including annual home-based HIV testing, promotion of medical male circumcision for HIV-negative men, and offer of immediate ART for those testing HIV-positive; Arm B will receive the full package except that ART initiation will follow current national guidelines; Arm C will receive standard of care. A Population Cohort of 2,500 adults will be randomly selected in each community and followed for 3 years to measure the primary outcome of HIV incidence. Based on model projections, the trial will be well-powered to detect predicted effects on HIV incidence and secondary outcomes. Trial results, combined with modelling and cost data, will provide short-term and long-term estimates of cost-effectiveness of UTT interventions. Importantly, the three-arm design will enable assessment of how much could be achieved by optimal delivery of current policies and the costs and benefits of extending this to UTT.Trial registration: ClinicalTrials.gov NCT01900977.
    Trials 02/2014; 15(1):57. DOI:10.1186/1745-6215-15-57 · 1.73 Impact Factor
Show more